Tali Czarnowicki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tali Czarnowicki has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
James G. Krueger
Laboratory for Investigative Dermatology The Rockefeller University New York NY USA
7 shared publicationsEmma Guttman-Yassky
Laboratory for Investigative Dermatology, Rockefeller University, New York, NY; Department of Dermatology and the Laboratory for Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, NY
6 shared publications- Emma Guttman-Yassky
Department of Dermatology, Icahn School of Medicine at Mount Sinai, NY
4 shared publications Juana Gonzalez
Translational Technology Core Laboratory, Rockefeller University, New York, NY
4 shared publicationsMayte Suárez-Fariñas
Department of Dermatology and the Laboratory for Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, NY; Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY; Department of Genetics and Genomics Science, Icahn Institute for Genomics and Multiscale Biology, New York, NY
4 shared publicationsAvner Shemer
Department of Dermatology, Tel-Hashomer Hospital, Tel Aviv, Israel
3 shared publications
Latest Publications
- 17 September 2026
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 95 (6) , 1893-1896
Bidirectional association between celiac disease and vitiligo: Two cohort analyses from the Clalit Health Services database
- 17 September 2026
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 95 (6) , 1893-1896
Bidirectional association between celiac disease and vitiligo: Two cohort analyses from the Clalit Health Services database
- Open Access
- 1 January 2026
- Published by XMLink in Annals of Dermatology
- Vol. 38 (3) , 177-182
Crisaborole 2% for Pediatric Periorificial Dermatitis: A Randomized, Double-Blind, Vehicle-Controlled Pilot Study
Ollech A, et al. Ann Dermatol. 2026 Jun;38(3):177-182. https://doi.org/10.5021/ad.25.227
- 1 January 2026
- Published by XMLink in Annals of Dermatology
- Vol. 38 (3) , 177-182
Open AccessCrisaborole 2% for Pediatric Periorificial Dermatitis: A Randomized, Double-Blind, Vehicle-Controlled Pilot Study
Ollech A, et al. Ann Dermatol. 2026 Jun;38(3):177-182. https://doi.org/10.5021/ad.25.227
- Open Access
- 29 October 2025
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (4) , 763-773
Comorbidities and Healthcare Utilization in 4197 Patients With Prurigo Nodularis in Israel: A Cross‐Sectional Population‐Based Analysis
Background: Prurigo nodularis patients face a significant burden of comorbidities, necessitating a comprehensive approach to care. We aimed to explore the association between prurigo nodularis, its comorbid conditions, and healthcare usage patterns. Methods: A population‐based, cross‐sectional study was conducted using the computerized medical data of Clalit Health Service, the largest health maintenance organization in Israel. We extracted data on all database members with prurigo nodularis between the years 2000 and 2022. Data was gathered from various sources, including primary care and hospital reports, as well as laboratory and imaging analyses. We compared 4197 prurigo nodularis patients with 40,771 matched controls (age, gender, socioeconomic status, ethnicity). Logistic regression was used to calculate odds ratios (OR) for comorbidities. Healthcare utilization and medication claims were also analyzed. Results: This study involved 4197 prurigo nodularis patients. Prurigo nodularis showed strong associations with various cutaneous and systemic comorbidities, mainly atopic dermatitis (odds ratio [OR] 5.74, 99.5% confidence interval [CI]: 4.85–6.80, p < 0.001), chronic renal failure and dialysis (OR 1.41, 99.5% CI: 1.15–1.72, p < 0.001), as well as a myriad of mental health disorders. Prurigo nodularis patients exhibited increased healthcare utilization and medication claims. Conclusions: This study highlights the substantial comorbidity burden in prurigo nodularis patients, emphasizing the need for a holistic care approach. The study also underscores the importance of psychological screening and highlights the burden that prurigo nodularis and its associated disorders place on healthcare utilization. Future studies that include further research into prurigo nodularis pathogenesis and treatment strategies considering its systemic associations are warranted.
- 29 October 2025
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (4) , 763-773
Open AccessComorbidities and Healthcare Utilization in 4197 Patients With Prurigo Nodularis in Israel: A Cross‐Sectional Population‐Based Analysis
Background: Prurigo nodularis patients face a significant burden of comorbidities, necessitating a comprehensive approach to care. We aimed to explore the association between prurigo nodularis, its comorbid conditions, and healthcare usage patterns. Methods: A population‐based, cross‐sectional study was conducted using the computerized medical data of Clalit Health Service, the largest health maintenance organization in Israel. We extracted data on all database members with prurigo nodularis between the years 2000 and 2022. Data was gathered from various sources, including primary care and hospital reports, as well as laboratory and imaging analyses. We compared 4197 prurigo nodularis patients with 40,771 matched controls (age, gender, socioeconomic status, ethnicity). Logistic regression was used to calculate odds ratios (OR) for comorbidities. Healthcare utilization and medication claims were also analyzed. Results: This study involved 4197 prurigo nodularis patients. Prurigo nodularis showed strong associations with various cutaneous and systemic comorbidities, mainly atopic dermatitis (odds ratio [OR] 5.74, 99.5% confidence interval [CI]: 4.85–6.80, p < 0.001), chronic renal failure and dialysis (OR 1.41, 99.5% CI: 1.15–1.72, p < 0.001), as well as a myriad of mental health disorders. Prurigo nodularis patients exhibited increased healthcare utilization and medication claims. Conclusions: This study highlights the substantial comorbidity burden in prurigo nodularis patients, emphasizing the need for a holistic care approach. The study also underscores the importance of psychological screening and highlights the burden that prurigo nodularis and its associated disorders place on healthcare utilization. Future studies that include further research into prurigo nodularis pathogenesis and treatment strategies considering its systemic associations are warranted.
- 22 April 2025
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 156 (2) , 237-251
Converging paths toward unified therapeutic approaches in atopic dermatitis, vitiligo, and alopecia areata
- 22 April 2025
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 156 (2) , 237-251
Converging paths toward unified therapeutic approaches in atopic dermatitis, vitiligo, and alopecia areata
- 2 December 2024
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 92 (4) , 741-752
Evaluating cancer risk in a large cohort of 25,008 patients with vitiligo: Insights from a comprehensive cohort population-based study
- 2 December 2024
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 92 (4) , 741-752
Evaluating cancer risk in a large cohort of 25,008 patients with vitiligo: Insights from a comprehensive cohort population-based study
- 1 August 2024
- Published by Frontline Medical Communications, Inc. in Cutis
- Vol. 114 (2) , 55-59
Association Between Pruritus and Fibromyalgia: Results of a Population-Based, Cross-Sectional Study
Fibromyalgia is a common musculoskeletal condition that affects up to 3% of the worldwide population. Its pathogenesis is not entirely clear but is thought to involve neurogenic inflammation as well as aberrations in peripheral nerves and central pain mechanisms. It is believed that the same mechanism that causes hypersensitivity and pain in patients with fibromyalgia also predisposes them to pruritus. This population-based, retrospective, cross-sectional study was performed using a computerized database encompassing more than 4.5 million patients to examine the association between fibromyalgia and pruritus as well as pruritus-related skin conditions.
- 1 August 2024
- Published by Frontline Medical Communications, Inc. in Cutis
- Vol. 114 (2) , 55-59
Association Between Pruritus and Fibromyalgia: Results of a Population-Based, Cross-Sectional Study
Fibromyalgia is a common musculoskeletal condition that affects up to 3% of the worldwide population. Its pathogenesis is not entirely clear but is thought to involve neurogenic inflammation as well as aberrations in peripheral nerves and central pain mechanisms. It is believed that the same mechanism that causes hypersensitivity and pain in patients with fibromyalgia also predisposes them to pruritus. This population-based, retrospective, cross-sectional study was performed using a computerized database encompassing more than 4.5 million patients to examine the association between fibromyalgia and pruritus as well as pruritus-related skin conditions.
- 27 July 2024
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 50 (6) , 1138-1145
High socioeconomic status is significantly associated with psoriasis: results from a cross-sectional, population-based study of 129 855 patients
Background: While the contribution of environmental factors (including smoking, overweight and stress) to psoriasis has been validated, data mining for the association between socioeconomic status (SES) and psoriasis prevalence has yielded contradictory observations. Objectives: To evaluate the association between psoriasis prevalence and SES. Methods: This was a nationwide population-based cross-sectional retrospective study that included all patients insured by ‘Clalit’ Health Services (N = 4 604 994). Univariable and multivariable logistic regression analyses were conducted to explore the association between psoriasis and SES while controlling for potential sociodemographic and clinical confounders. Results: The study population included 129 855 patients with psoriasis and 4 475 139 individuals without psoriasis. Higher SES was associated with an increased prevalence of psoriasis; in a fully adjusted model, Clalit members within the highest SES were 1.43-fold more likely to have psoriasis [95% confidence interval (CI) 1.39–1.48, P < 0.001], and those in the medium SES group were 1.2-fold more likely to have psoriasis compared with those in the lowest SES group (95% CI 1.18–1.26, P < 0.001; P for linear trend < 0.001). Conclusions: Positive correlation was found between SES and psoriasis prevalence. Further investigation is warranted to elucidate the factors accounting for this observation.
- 27 July 2024
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 50 (6) , 1138-1145
High socioeconomic status is significantly associated with psoriasis: results from a cross-sectional, population-based study of 129 855 patients
Background: While the contribution of environmental factors (including smoking, overweight and stress) to psoriasis has been validated, data mining for the association between socioeconomic status (SES) and psoriasis prevalence has yielded contradictory observations. Objectives: To evaluate the association between psoriasis prevalence and SES. Methods: This was a nationwide population-based cross-sectional retrospective study that included all patients insured by ‘Clalit’ Health Services (N = 4 604 994). Univariable and multivariable logistic regression analyses were conducted to explore the association between psoriasis and SES while controlling for potential sociodemographic and clinical confounders. Results: The study population included 129 855 patients with psoriasis and 4 475 139 individuals without psoriasis. Higher SES was associated with an increased prevalence of psoriasis; in a fully adjusted model, Clalit members within the highest SES were 1.43-fold more likely to have psoriasis [95% confidence interval (CI) 1.39–1.48, P < 0.001], and those in the medium SES group were 1.2-fold more likely to have psoriasis compared with those in the lowest SES group (95% CI 1.18–1.26, P < 0.001; P for linear trend < 0.001). Conclusions: Positive correlation was found between SES and psoriasis prevalence. Further investigation is warranted to elucidate the factors accounting for this observation.
- 28 June 2023
- Published by Wolters Kluwer Health in Current Opinion in Allergy and Clinical Immunology
- Vol. 23 (5) , 446-453
The pathogenetic role of Th17 immune response in atopic dermatitis
Purpose of review: As we continue to unravel the pathophysiology and immune mechanisms underlying atopic dermatitis (AD), the emergence of targeted treatments has provided new options for management. Although there are available therapies targeting various immune pathways in AD, the precise pathogenic role of interleukin (IL)-17 in AD pathogenesis remains unclear. The objective of this review is to examine the existing data pertaining to the role of IL-17 in AD and shed light on the potential of targeting this pathway as a therapeutic approach in AD treatment. Recent findings: IL-17 has a dual role of pro-inflammatory and immune protective function, making it an important player in several autoimmune and inflammatory conditions. The extent of IL-17 axis involvement in AD pathogenesis is still debatable. Emerging data show that Th17-related cytokines/chemokines are elevated in skin and sera samples of AD patients, with some articles reporting correlations with disease severity. Particularly increased Th17 signature in specific AD patient subsets, such as Asian-origin or pediatric patients, suggests that certain patients’ disease presentations are more predominantly influenced by Th17, and, thus, they may benefit more from Th17 therapeutic targeting approaches. Lack of clinical efficacy with anti-Th17 biologics in AD patients, underscores the need to better elucidate the role of Th17 in AD pathogenesis, along with its utility in therapy. Summary: The well established role of IL-17 in autoimmune disorders hints for its possible participation in AD disease pathogenesis. Subsequent investigations are needed to assess whether the targeting of specific IL-17 isoforms, homodimers, or heterodimers in specific subpopulations of AD can modify treatment outcomes.
- 28 June 2023
- Published by Wolters Kluwer Health in Current Opinion in Allergy and Clinical Immunology
- Vol. 23 (5) , 446-453
The pathogenetic role of Th17 immune response in atopic dermatitis
Purpose of review: As we continue to unravel the pathophysiology and immune mechanisms underlying atopic dermatitis (AD), the emergence of targeted treatments has provided new options for management. Although there are available therapies targeting various immune pathways in AD, the precise pathogenic role of interleukin (IL)-17 in AD pathogenesis remains unclear. The objective of this review is to examine the existing data pertaining to the role of IL-17 in AD and shed light on the potential of targeting this pathway as a therapeutic approach in AD treatment. Recent findings: IL-17 has a dual role of pro-inflammatory and immune protective function, making it an important player in several autoimmune and inflammatory conditions. The extent of IL-17 axis involvement in AD pathogenesis is still debatable. Emerging data show that Th17-related cytokines/chemokines are elevated in skin and sera samples of AD patients, with some articles reporting correlations with disease severity. Particularly increased Th17 signature in specific AD patient subsets, such as Asian-origin or pediatric patients, suggests that certain patients’ disease presentations are more predominantly influenced by Th17, and, thus, they may benefit more from Th17 therapeutic targeting approaches. Lack of clinical efficacy with anti-Th17 biologics in AD patients, underscores the need to better elucidate the role of Th17 in AD pathogenesis, along with its utility in therapy. Summary: The well established role of IL-17 in autoimmune disorders hints for its possible participation in AD disease pathogenesis. Subsequent investigations are needed to assess whether the targeting of specific IL-17 isoforms, homodimers, or heterodimers in specific subpopulations of AD can modify treatment outcomes.
- 29 May 2021
- Published by Springer Nature
- p. 1-5
Contact Dermatitis: Irritant